An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.
Wu, N.C., Yuan, M., Liu, H., Lee, C.D., Zhu, X., Bangaru, S., Torres, J.L., Caniels, T.G., Brouwer, P.J.M., van Gils, M.J., Sanders, R.W., Ward, A.B., Wilson, I.A.(2020) Biorxiv 
- PubMed: 32743580 
- DOI: 10.1101/2020.07.26.222232
- Primary Citation of Related Structures:  
7JMP, 7JMO - PubMed Abstract: 
IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 due to structural constraints in ...